Property developer Drivas has lost its court fight over plans for a nine-storey tower atop the heritage-listed Murrays Building in Parramatta’s Centenary Square.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
Construction materials giant Boral has pleaded guilty to interfering with Indigenous relics at a Hobart quarry.
Real estate company Flemington Properties has won $5 million from Ausgrid in a commercial rent dispute, with a judge finding the state corporation was effectively asking the court to rewrite the parties’ agreement.
The competition regulator plans to block a group of Catholic hospital operators from collectively boycotting large private health insurers in the event funding negotiations fail.
The firm that represented the funder of the notorious Banksia class action faces potential proceedings by a group of debenture holders. Meanwhile, Banksia’s receiver wants a court direction that he is justified in not pursuing the lawyers.
Qantas has reached an agreement to pay $120 million in compensation to 1,800 ground crew staff who were found to have been illegally sacked.
The owners corporation of a Meriton apartment block in Sydney can add late evidence of alleged defects, despite a judge calling the case “an example of how proceedings in the Technology and Construction List should not be conducted”.
A court has approved a $26.5 million settlement in a shareholder class action against regenerative medicine company Mesoblast.
Herbert Smith Freehills has shown M&A partner Damien Hazard the door after he posted what the firm referred to as a “deeply offensive” tweet.